Description
Patients with advanced cutaneous squamous cell carcinoma (cSCC) who are not eligible for or have failed to respond to anti-PD1 immunotherapy have few treatment options. Epidermal growth factor receptor (EGFR) directed chimeric antigen recep…
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $258,346 at start, $328,966 after amendment #1 (+$70,620).
- #02025-05-01$258,346
- #12026-01-30$328,966+$70,620
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2025-05-01(start date) | $258,346 | — | Patients with advanced cutaneous squamous cell carcinoma (cSCC) who are not eligible for or have failed to res… |
| #1 amendment | 2026-01-30 | $328,966 | +$70,620 | Patients with advanced cutaneous squamous cell carcinoma (cSCC) who are not eligible for or have failed to res… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 119259505)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2025-2026-Q4-1040854 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives | $277,599 | FY2026 |
| 172-2024-2025-Q3-1023488 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives | $175,702 | FY2025 |
| 271-2024-2025-Q3-00051 | Health Canada | Santé Canada · Substance Use and Addictions Program | $196,656 | FY2025 |
| 271-2025-2026-Q3-00042 | Health Canada | Santé Canada · Substance Use and Addictions Program | $246,656 | FY2025 |
| 172-2023-2024-Q4-1015832 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program – Ideation Fund | $25,000 | FY2024 |
| 271-2023-2024-Q4-00074 | Health Canada | Santé Canada · Addressing Racism and Discrimination in Canada’s Health Systems Program | $85,000 | FY2024 |
Other recipients funded under "Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2026-2027-Q1-1044103 | York University | FY2027 | $462,000 | FY2027 |
| 172-2026-2027-Q1-1043787 | Simon Fraser University | FY2027 | $279,766 | FY2027 |
| 172-2026-2027-Q1-1044229 | Noram Electrolysis Systems Inc. | FY2027 | $300,053 | FY2027 |
| 172-2026-2027-Q1-1043305 | University of Ottawa | FY2027 | $418,000 | FY2027 |
| 172-2026-2027-Q1-1043602 | University of Windsor | FY2027 | $99,000 | FY2027 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2025-2026-Q1-1029941 · retrieved 2026-11-12.